Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545129 · ClinicalTrials.gov registry record · Phase 2
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00545129 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 59 participants.
The verdict
NCT00545129, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
Interventions
- DRUG Tanezumab 10 mg IV
- DRUG IV Placebo for tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-04-29 |
| Est. Completion | 2012-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545129
The ClinicalTrials.gov registry entry for NCT00545129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tanezumab 10 mg IV is the first listed.
NCT00545129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00545129 about?
NCT00545129 is a clinical study titled "A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone". The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
What is the current status of trial NCT00545129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2009-04-29. Estimated completion is 2012-02-07.
What interventions are being tested in trial NCT00545129?
The interventions under investigation include: Tanezumab 10 mg IV (DRUG), IV Placebo for tanezumab (DRUG).
Who is sponsoring clinical trial NCT00545129?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.